Japan’s Pharmaceuticals and Medical Devices Agency has approved the combination of pembrolizumab and axitinib for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma.
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.
Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.
Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.
Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.
Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.
A high rate of patients with breast cancer and other solid tumors were rechallenged with trastuzumab deruxtecan after grade 1 interstitial lung disease.
